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Background: Blastocystosis is a frequent bowel disease. We planned to to evaluate the prevalence of Blastocystis
spp. in patients who applied to the same internal medicine-gastroenterology clinic with or without gastrointestinal
complaints to reveal the association of this parasite with diagnosed IBS and IBD.
Methods: A total of 2334 patients with gastrointestinal symptoms composed the study group, which included 335
patients with diagnosed inflammatory bowel disease and 877 with irritable bowel syndrome. Patients without any
gastrointestinal symptoms or disease (n = 192) composed the control group. Parasite presence was investigated by
applying native-Lugol and formol ethyl acetate concentration to stool specimens, and trichrome staining method in
suspicious cases.
Results: Blastocystis spp. was detected in 134 patients (5.74%) in the study group and 6 (3.12%) in the control
group (p = 0.128). In the study group, Blastocystis spp. was detected at frequencies of 8.7% in ulcerative colitis
(24/276), 6.78% in Crohn’s disease (4/59), 5.82% in irritable bowel syndrome (51/877), and 4.9% in the remaining
patients with gastrointestinal symptoms (55/1122). Blastocystis spp. was detected at a statistically significant ratio in
the inflammatory bowel disease (odds ratio [OR] = 2.824; 95% confidence interval [CI]: 1.149-6.944; p = 0.019) and
ulcerative colitis (OR = 2.952; 95% CI: 1.183-7.367; p = 0.016) patients within this group compared to controls. There
were no statistically significant differences between the control group and Crohn’s disease or irritable bowel
syndrome patients in terms Blastocystis spp. frequency (p = 0.251, p = 0.133).
Conclusions: Blastocystosis was more frequent in patients with inflammatory bowel disease, especially those with
ulcerative colitis. Although symptomatic irritable bowel syndrome and Crohn’s disease patients had higher rates of
Blastocystis spp. infection, the differences were not significant when compared to controls.
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Blastocystis spp. is a unicellular protozoan found in the
large intestine in humans. While Blastocystis infection is
common worldwide, it is observed more frequently in
tropical climates and developing countries with a wide
host population including mammals, birds, reptiles, and
arthropods [1]. The parasite spreads through the fecal-
oral route particularly under poor hygiene conditions [2]
and use of unboiled water has been considered to have a
significant role in the spread of the infection [3]. Six
forms have been defined to date in the culture and direct* Correspondence: ayhancekin@hotmail.com
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reproduction in any medium, provided the orstool analysis while the vacuolar form is the most fre-
quently form encountered in the stool [4]. Diagnosis
of infection is generally made by demonstrating the
vacuolar form in the direct microscopic examination of
the stool with presence of more than five parasites in
a microscope field at X40 magnification accepted as
pathogenic [5]. Until recently, it was accepted that
only one Blastocystis species (Blastocystis hominis)
infected human beings. However, in recent years, it
was demonstrated that nine different species may in-
fect humans [6].
Untreated Blastocystis spp. can accommodate in the
human gastrointestinal system for a few weeks up to a
few years [2]. The pathogenic potential of Blastocystis
spp. is still a debated issue due to the fact it is the mosttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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as well as patients with gastrointestinal symptoms [1,4].
Blastocystis spp. infection is generally asymptomatic.
Symptomatic cases are characterized by nonspecific
gastrointestinal symptoms such as nausea, anorexia,
weight loss, weakness, dizziness, and gas, together with
mainly diarrhea or abdominal pain [7]. In addition, it was
also reported that the parasite can be encountered to-
gether with serious cases such as rectal bleeding, weight
loss, anemia, and eosinophilia [2]. For example, Carras-
cosa et al. reported a B. hominis-associated hemorrhagic
proctosigmoiditis case [8]. Blastocystis spp.-induced
superficial intestinal invasion and mucosal inflammation
was demonstrated in animal studies [9] while the patho-
genic role of Blastocystis spp. in bowel inflammation has
been investigated in many clinical trials.
Although the association of Blastocystis spp. with irrit-
able bowel syndrome (IBS) and inflammatory bowel dis-
ease (IBD) have been reported to be frequently
encountered in daily practice, its role in the pathogenesis
is still debated [10,11]. Therefore, the present study was
designed to evaluate the prevalence of Blastocystis spp.
in patients who applied to the same internal medicine-
gastroenterology clinic with or without gastrointestinal
complaints to reveal the association of this parasite with
diagnosed IBS and IBD.Methods
Study population
A total of 2526 patients who applied to the Gastroenter-
ology Clinic of Antalya Training and Research Hospital
from January 2010 to May 2011 were included in this
retrospective case–control study based on presence of data
on routine stool microscopy, stool culture and parasitic
investigations by a gastroenterology specialist. Patients ad-
mitting with gastrointestinal complaints (n=2334) includ-
ing acute diarrhea, loss of appetite, dyspepsia, constipation,
and abdominal pain composed the study group while a
control group (n=192) was selected from population
attending the outpatient department within the similar
time period on an outpatient basis for routine control
without any accompanying gastrointestinal symptoms.
Patients in the control group were not diagnosed with any
gastrointestinal diseases (IBD, IBS etc.) and, they were also
checked for fecal occult blood.
The patients who had positive stool culture results for
pathogenic bacterias (Campylobacter, Salmonella, Shi-
gella, enteropathogenic E. coli etc.) and the patients
whose direct microscopic stool examination revealed
pathogenic parasites (Giardia lamblia, Entamoeba histo-
lytica etc.) were excluded from the study.
The study protocol was approved by the Ethics Com-
mittee of Antalya Training and Research Hospital.Assessments
IBS patients were diagnosed according to Rome III criteria
the diagnosis of IBD was based on detailed clinical find-
ings and endoscopic and histopathological examinations
including ulcerative colitis (UC) and Crohn’s disease (CD).
Stool specimens were evaluated microscopically after
macroscopic analysis. For this purpose, native-Lugol and
formol ethyl acetate concentration method was applied to
these stool specimens initially, and suspicious cases were
analyzed by trichrome staining method. Samples were pre-
pared with native–Lugol, formol ethyl acetate concentra-
tion method, or trichrome staining method, and were
examined under light microscope at X40, X10 or X100
magnification, respectively. All samples were evaluated by
experienced parasitology specialists and the results were
recorded. A sample was accepted as positive for Blastocys-
tis spp. if five or more parasites were identified in every
microscopic field at X40 magnification.
Statistical analysis
Fisher’s exact test and Pearson chi-square analysis per-
formed for categorical variables using the Statistical Pack-
age for the Social Sciences (SPSS) 13.0 and a two-sided
p-value < 0.05 was considered statistically significant.
Results
Gastrointestinal diagnoses in the study group
Evaluation of the study group revealed the diagnosis of a
gastrointestinal disease in 1212 patients including IBD
(335, 14.4%) or IBS (877, 37.6%) based on clinical and la-
boratory tests. Of 335 patients with IBD, 276 patients
were determined to have UC while CD disease was
determined in 59 patients. A total of 32 patients with
IBD were newly diagnosed during the study including 28
UC and 4 CD cases while rest of IBD patients (n = 303)
had been followed as IBD previously.
Frequency of Blastocystis spp. infections in the study vs.
control group
Overall, Blastocystis spp. was found in 134 cases (5.74%)
out of 2334 patients in the study group who applied to the
gastroenterology clinic with gastrointestinal complaints
while in 6 patients (3.12%) in the control group (n= 192)
who applied to the same clinic without gastrointestinal
complaints [Table 1]. There was no statistically significant
difference between the study and control groups in terms
of frequency of Blastocystis spp. (p = 0.128).
Consideration of Blastocystis spp., frequency in the
study group with respect to diagnosis revealed the iden-
tification of Blastocystis spp. in significantly higher num-
ber of patients with IBD (28 of 335, 8.35%) patients
when compared to control group (OR= 2.824; 95% CI:
1.149–6.944; p = 0.019). However there was no signifi-
cant difference between patients with IBS (51 of 877
Table 1 Demographic and clinical characteristics and




Demographic and clinical characteristics
Age (years); mean (SD) 45.8(16.2) 45.2(13.2) 47.3(16.1) 45.5(15.2)
Gender
Male% 39.6 41.8 44.9 42.4
Female% 60.4 58.2 55.1 57.6
Clinical Symptoms%
Abdominal pain 79.8 83.5 81.1
Constipation 50.2 14.9 49.5
Diarrhea 34.2 89.5 48.8
Bloating 79.8 74.6 71.3
Flatulence 50.2 59.7 54.3
Blastocystis spp. infections








IBD 28 8.35 335
UC 24 8.70 276
CD 4 6.78 59
IBS 51 5.82 877
Controls 6 3.12 192
IBS: Irritable bowel syndrome; IBD: Inflammatory bowel disease; UC: Ulcerative
colitis; CD: Crohn’s disease.
Cekin et al. BMC Gastroenterology 2012, 12:122 Page 3 of 6
http://www.biomedcentral.com/1471-230X/12/1/122patients, 5.82%) and control group in terms of Blastocys-
tis spp. frequency (p = 0.133). When the two types of
IBD were evaluated in terms of Blastocystis spp. fre-
quency compared to control group, Blastocystis spp.
frequency was determined to be significantly higher in
UC patients (24 of 276 UC patients, 8.7%) than con-
trol patients (OR= 2.952; 95% CI: 1.183-7.367;
p = 0.016), while there was no significant difference be-
tween patients with CD (4 out of the 59 patients,
6.78%) and control group in terms of Blastocystis spp.
frequency (p = 0.251). Only one UC patient - out of 32
newly diagnosed IBD patients - had Blastocystis spp. in
their stool examinations. Considering patients admit-
ting with gastrointestinal symptoms but not diagnosed
with IBD or IBS (n = 1122), Blastocystis spp. was found
in 4.9% (n = 55) of these patients and there was no
statistical difference when compared with either the
control group (p = 0.280) or the other symptomatic
patients (p = 0.055) (Table 1).Demographic and clinical characteristics of patients and
control group
The mean (SD) age of patients with IBS, patient with
IBD, patients with gastrointestinal complaints and the
control group were 45.8 (16.2), 45.2 (13.2), 47.3 (16.1),
and 45.5 (15.2) years, respectively with no statistically
significant difference between groups (p = 0.597). The
groups were also comparable to each other in terms of
gender (Table 1).
In patients with gastrointestinal complaints, gender
distribution was homogenous in patients with (n = 134;
83 (62%) females and 51 (38%) males) or without Blasto-
cystis spp. (n = 2200; 1260 (57.3%) females and 940
(42.7%) males) (p = 0.366).Discussion
Blastocystis spp. is the most common parasite found in
human stool specimens [12] with prevalence reported to
range from 1.5% and 10% in developed countries and
from 30% and 50% in developing countries [1,2,13]. The
parasite was encountered 28.5 times more than Giardia
lamblia in a study conducted in the United States in
2000 [14]. In another study on the epidemiology of Blas-
tocystis spp. conducted in the United States in 2006,
16,374 stool specimens were analyzed, and prevalence of
Blastocystis spp. was found at a ratio of 18% [15]. In our
study, the Blastocystis spp. ratios in patients with intes-
tinal complaints and in the control group were 5.74%
and 3.12%, respectively. This ratio is close to the ratio
reported in the developed countries and also is in paral-
lel with ratios (ranges from 1.4% to 44.3%) reported from
Turkey to date. The fact that the criterion for Blastocys-
tis spp. positivity has been accepted as the presence of
five or more parasites in the microscopic field at X40
magnification in some of the studies, whereas consider-
ation of positivity regardless of the number in others
may explain the wide range of prevalence reported in
the literature.
Although the specific pathogenicity of Blastocystis spp.
is still undetermined, the intestinal inflammation induced
by this parasite was reported to yield specific inflamma-
tory changes in the gut wall. In this regard, in an experi-
mental animal model study in mice, vacuolar form of the
parasite was reported to cause invasion to the lamina
propria, submucosal and muscular layers of the large in-
testine leading mixed inflammatory cell infiltration and
active colitis in infected mice [16]. Although there are
case reports on the pathogenicity of Blastocystis spp. in
humans, the number of those studies is inadequate
[17,18]. Nonetheless, proteases of Blastocystis spp. were
considered a virulence factor that is responsible for pro-
tein degredation and have possible pathogenic role in
host immune evasion [19].
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reported to include asymptomatic, acute symptomatic
and chronic symptomatic cases in the past studies based
on use of different methologies and study populations.
In a study in 2010, B. hominis was reported to be more
frequent in patients with intestinal symptoms than in
the asymptomatic patients (5.67% vs. 3.43%, respectively)
[20]. In our study, albeit not statistically significant, fre-
quency of blastocystis infection was also higher in symp-
tomatic than asymptomatic patients (5.74% vs 3.12%).
Researchers report that Blastocystis spp. is the most
common parasite encountered in symptomatic patients
based on two main reasons. Firstly, clinicians are reluc-
tant to treat this parasite due to its low pathogenicity
and self-restricting symptomatology; and secondly, Blas-
tocystis spp. that are resistant to other antiparasitic med-
ications have the ability to colonize easily into empty
intestinal niches after the treatment of other pathogenic
protozoa with conventional medications [7,21].
Although no clear correlation between diarrhea and
Blastocystis spp. could be established by means of the
controlled studies conducted to date, its relation with
chronic bowel diseases of unknown origin such as IBD
and IBS is currently being investigated due to the in-
creasing prevalence of this parasite in developed
countries.
Being a functional bowel disorder associated with ab-
dominal pain or discomfort and defecation disorders, IBS
is generally considered a psychosomatic disease, etiology
of which has not been clarified yet [22]. IBS prevalence in
developing countries varies between 35%-43% and it is a
frequent disease in the clinical practice with 12% of the
general medical visits and 25-50% of gastroenterology
consultations resulting with the positive diagnosis [23].
Although IBS is a functional bowel disease, studies on
the association between Blastocystis spp. and IBS
revealed that parasite infection was evident in almost half
of the patients with IBS [11,24,25]. Accordingly, Yakoob
et al. reported that 52% of IBS patients and 24% of the
control group had Blastocystis spp. infection [10]. In
other related studies, B. hominis was found in 17.3% of
symptomatic patients with IBS and in 6% of cases in the
asymptomatic control group, and the difference between
the two groups was reported to be significant [26]. In our
study, patients with blastocystis infection and IBS
demonstrated similar symptomatology in parallel with
the literature. However, while there was a significant par-
allelism between the frequency of blastocystis infection
and IBS prevalence in studies conducted in different
countries, [24]. Blastocystis spp. was found in 51 (5.82%)
of 877 symptomatic patients in our study with no statisti-
cally significant difference compared with the ratio
obtained in the asymptomatic control group (3.12%)
(p = 0.133).The IBD sub-group (n = 335) of patients with gastro-
intestinal complaints (n = 2334) was determined to have
the most frequent Blastocystis spp. infection (8.35%) with
significantly higher rates compared with the controls
(3.12%; p = 0.019) Likewise, 24 of 28 patients with Blas-
tocystis spp in the IBD group were UC patients (n = 276)
with significantly higher rate of infection (8.7%) in these
patients compared to controls (3.12%, p = 0.016). How-
ever, while showing a tendency towards higher ratio in
patients with CD, there was no statistical difference be-
tween CD patients (6.78%) and control group in terms
of frequency of Blastocystis spp. infection (p = 0.251).
UC is a chronic inflammatory disease of the intestines
manifesting itself with consequent activity and remission
periods. Many studies have investigated the influence of
intestinal infections on the clinical course of UC. In this
respect, in a prospective case-controlled study by
Yamamoto-Furusho et al. conducted in Mexico on the
correlation of UC disease with parasite infections, Blas-
tocystis spp. was reported as the most common parasite,
at a rate of 10%, which is very similar to prevalence of
parasite in our study (8.7%). They also reported that
presence of Blastocystis spp., Entamoeba histolytica and
Entamoeba coli was correlated with relapsing illness
[27]. In another study, six UC patients with refractory
symptoms were found to have B. hominis in their stool
examinations with complete recovery by 14-day metro-
nidazole treatment [28]. In a study by Mylonaki et al.
emphasizing the importance of routine microscopic
stool analysis in IBD exacerbation, Blastocystis spp. was
amongst the detected enteric infectious agents [29].
These results suggested the correlation of Blastocystis
spp. with IBD and strengthened the hypothesis that the
parasite may have a role in the exacerbation of diseases
[28]. In contrast, Nagler et al. reported that Blastocystis
spp. was not a significant pathogen in IBD exacerbations.
However, they examined only 12 patients retrospectively,
so the lack of Blastocystis spp. might be associated with
the inadequate number of patients examined [30].
In our study, a significant rate of Blastocystis spp. in-
fection was detected in patients with gastrointestinal
symptoms via common laboratory methods. However,
there are studies reporting that the sensitivity of the
standard methods used in clinical practice are lower
than that of molecular methods and culture [31]. While
it has long been accepted that B. hominis is the single
blastocyst specie infecting humans, genetic analysis con-
ducted recently demonstrated that nine different types
of blastocyst may infect humans. Besides, antigenic het-
erogeneity of Blastocystis spp. supports the likelihood of
virulent and avirulent species of this parasite [32]. In this
regard, starting from the hypothesis of Boorom, more
virulent and easily transmissible Blastocystis spp. may be
the cause of the increase in the prevalence of IBDs in
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sensitive methods such as polymerase chain reaction
and culture in detection of more virulent types of this
parasite.
The major limitation of the present study is the case–
control design increasing the likelihood of confounding
variables and bias (sampling and observation and recall
bias). Nevertheless, a convenience sample (sampled in
the same way as the cases) was selected from population
attending the same outpatient department to overcome
sampling bias and to enable the controls to represent
the same population as the cases. Besides, the likelihood
of retrospective recall bias seems to be minimized by
using data recorded, for other purposes, before the out-
come had occurred and therefore before the study had
started. We didn’t assess the potential viral causes of the
gastrointestinal complaints and this is the limitation of
our study. Another limitation important in terms of clin-
ical relevance of our findings is the neglect of including
ulcerative colitis activation criteria in the diagnostic
evaluation of patients in the study group. For this rea-
son, albeit its clinical importance, we are unable to draw
a conclusion regarding the causative role of Blastocysto-
sis infection among UC patients admitting with exacer-
bation of the disease.
Conclusions
Blastocystis spp. infection was more frequent in patients
with IBD, especially those with UC. Although symptom-
atic IBS and CD patients had higher rates of Blastocystis
spp. infection, there were no statistically significant dif-
ferences when compared to the control group. We think
that controlled studies on symptomatic patients and
especially in UC patients will disclose the role of Blas-
tocystis spp. in the pathogenesis as well as clinical
course of IBS and IBD.
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